Second- and third-generation ALK inhibitors for non-small cell lung cancer
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Second- and third-generation ALK inhibitors for non-small cell lung cancer
Authors
Keywords
Brain Metastasis, Pemetrexed, Anaplastic Lymphoma Kinase, Anaplastic Large Cell Lymphoma, Crizotinib
Journal
Journal of Hematology & Oncology
Volume 9, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-03-08
DOI
10.1186/s13045-016-0251-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Extended Survival and Prognostic Factors for Patients WithALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastasis
- (2016) Kimberly L. Johung et al. JOURNAL OF CLINICAL ONCOLOGY
- Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F
- (2016) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Severe contact esophagitis in a patient taking crizotinib: A case report
- (2015) Ciara Conduit et al. Asia-Pacific Journal of Clinical Oncology
- Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas
- (2015) Michela Boi et al. BRITISH JOURNAL OF HAEMATOLOGY
- PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models
- (2015) Helen Y. Zou et al. CANCER CELL
- Novel ALK fusion partners in lung cancer
- (2015) Aglaya G. Iyevleva et al. CANCER LETTERS
- Abstract 781: The potent ALK inhibitor AP26113 can overcome mechanisms of resistance to first- and second-generation ALK TKIs in preclinical models
- (2015) Sen Zhang et al. CANCER RESEARCH
- Abstract 764: Rational combination of PF-06463922 (next-generation ALK inhibitor) with PI3K pathway inhibitors overcomes ALKi resistance in EML4-ALK+ NSCLC models
- (2015) Ping Wei et al. CANCER RESEARCH
- Tackling Crizotinib Resistance: The Pathway from Drug Discovery to the Pediatric Clinic
- (2015) E. R. Tucker et al. CANCER RESEARCH
- Abstract 2827: Discovery of AP26113, a potent, orally active inhibitor of anaplastic lymphoma kinase and clinically relevant mutants
- (2015) Wei-Sheng Huang et al. CANCER RESEARCH
- Therapeutic management of ALK+nonsmall cell lung cancer patients
- (2015) Boris Duchemann et al. EUROPEAN RESPIRATORY JOURNAL
- Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastases
- (2015) Daniel B. Costa et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy inEGFR-Mutant Lung Cancer: A Meta-Analysis
- (2015) Chee Khoon Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- Novel ALK inhibitors in clinical use and development
- (2015) Chaitanya Iragavarapu et al. Journal of Hematology & Oncology
- Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status
- (2015) Wenzhao Zhong et al. Journal of Hematology & Oncology
- Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutation
- (2015) Shuhang Wang et al. Journal of Hematology & Oncology
- Advances in the management of gastrointestinal cancers—an upcoming role of immune checkpoint blockade
- (2015) Gaurav Goel et al. Journal of Hematology & Oncology
- Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer
- (2015) Wei Sun et al. Journal of Hematology & Oncology
- Nivolumab plus ipilimumab in the treatment of advanced melanoma
- (2015) Katy K. Tsai et al. Journal of Hematology & Oncology
- Programmed death 1 blockade, an Achilles heel for MMR-deficient tumors?
- (2015) Andy Yingjie Lin et al. Journal of Hematology & Oncology
- Bispecific antibodies and their applications
- (2015) Gaowei Fan et al. Journal of Hematology & Oncology
- Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future
- (2015) Gaurav Goel et al. Journal of Hematology & Oncology
- CSF Concentration of Crizotinib in Two ALK-Positive Non–Small-Cell Lung Cancer Patients with CNS Metastases Deriving Clinical Benefit from Treatment
- (2015) Giulio Metro et al. Journal of Thoracic Oncology
- Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
- (2015) Max S Topp et al. LANCET ONCOLOGY
- Successful treatment with alectinib after crizotinib-induced esophageal ulceration
- (2015) Yasuto Yoneshima et al. LUNG CANCER
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma
- (2015) N. R. Infarinato et al. Cancer Discovery
- Complex renal cysts associated with crizotinib treatment
- (2015) Patrick Schnell et al. Cancer Medicine
- Updated Evidence on the Mechanisms of Resistance to ALK Inhibitors and Strategies to Overcome Such Resistance: Clinical and Preclinical Data
- (2015) Gouji Toyokawa et al. Oncology Research and Treatment
- Multicystic kidney disease: A complication of crizotinib
- (2015) P. Souteyrand et al. Diagnostic and Interventional Imaging
- Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer
- (2015) Hideko Isozaki et al. Cancers
- Looking for a new panacea in ALK-rearranged NSCLC: may be Ceritinib?
- (2014) Christian Rolfo et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Strategies for modern biomarker and drug development in oncology
- (2014) Alan D Smith et al. Journal of Hematology & Oncology
- Nucleo-cytoplasmic transport as a therapeutic target of cancer
- (2014) Giovanni Luca Gravina et al. Journal of Hematology & Oncology
- Notch signaling and EMT in non-small cell lung cancer: biological significance and therapeutic application
- (2014) Xun Yuan et al. Journal of Hematology & Oncology
- Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies
- (2014) Raoul Tibes et al. Journal of Hematology & Oncology
- Refining the Toxicity Profile of Crizotinib
- (2014) Benjamin Solomon Journal of Thoracic Oncology
- Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
- (2014) Shirish M Gadgeel et al. LANCET ONCOLOGY
- A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+tumor cells
- (2014) Uwe Reusch et al. mAbs
- Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
- (2014) NEW ENGLAND JOURNAL OF MEDICINE
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Approval After Phase I: Ceritinib Runs the Three-Minute Mile
- (2014) B. A. Chabner ONCOLOGIST
- The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer
- (2014) L. Friboulet et al. Cancer Discovery
- Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials
- (2013) Thomas H. Marsilje et al. JOURNAL OF MEDICINAL CHEMISTRY
- Large-Scale Screening and Molecular Characterization of EML4-ALK Fusion Variants in Archival Non–Small-Cell Lung Cancer Tumor Specimens Using Quantitative Reverse Transcription Polymerase Chain Reaction Assays
- (2013) Tianhong Li et al. Journal of Thoracic Oncology
- CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study
- (2013) Takashi Seto et al. LANCET ONCOLOGY
- Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
- (2013) Muhammed Murtaza et al. NATURE
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2013) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants
- (2012) J. M. Heuckmann et al. CLINICAL CANCER RESEARCH
- Preclinical Rationale for Use of the Clinically Available Multitargeted Tyrosine Kinase Inhibitor Crizotinib in ROS1-Translocated Lung Cancer
- (2012) Hiroyuki Yasuda et al. Journal of Thoracic Oncology
- Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
- (2012) D Ross Camidge et al. LANCET ONCOLOGY
- Histologic and cytomorphologic features of ALK-rearranged lung adenocarcinomas
- (2012) Michiya Nishino et al. MODERN PATHOLOGY
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
- (2012) R. Katayama et al. Science Translational Medicine
- Comprehensive Histologic Analysis of ALK-Rearranged Lung Carcinomas
- (2011) Akihiko Yoshida et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802)
- (2011) Kazutomo Kinoshita et al. BIOORGANIC & MEDICINAL CHEMISTRY
- CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant
- (2011) Hiroshi Sakamoto et al. CANCER CELL
- ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors
- (2011) J. M. Heuckmann et al. CLINICAL CANCER RESEARCH
- CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib
- (2011) Daniel B. Costa et al. JOURNAL OF CLINICAL ONCOLOGY
- Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
- (2011) J. Jean Cui et al. JOURNAL OF MEDICINAL CHEMISTRY
- Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib
- (2011) Vince D. Cataldo et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers
- (2010) T. Sasaki et al. CANCER RESEARCH
- The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene
- (2010) Fergal C. Kelleher et al. EUROPEAN JOURNAL OF CANCER
- EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
- (2010) Young Lim Choi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy
- (2009) Thomas R Webb et al. Expert Review of Anticancer Therapy
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
- (2009) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- EML4-ALK: Honing In on a New Target in Non–Small-Cell Lung Cancer
- (2009) Leora Horn et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of Novel Isoforms of the EML4-ALK Transforming Gene in Non-Small Cell Lung Cancer
- (2008) Y. L. Choi et al. CANCER RESEARCH
- Multiplex Reverse Transcription-PCR Screening for EML4-ALK Fusion Transcripts
- (2008) K. Takeuchi et al. CLINICAL CANCER RESEARCH
- Detection of Mutations inEGFRin Circulating Lung-Cancer Cells
- (2008) Shyamala Maheswaran et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search